Quantcast

Latest Dopamine agonists Stories

2010-05-12 07:00:00

WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while levodopa remains the gold standard for Parkinson's disease treatment, physicians say they will increasingly use other agents to delay the need for levodopa. According to the new report entitled Treatment Algorithms in Parkinson's Disease, 46 percent of surveyed neurologists say it is "very likely" or "likely" they will...

2010-05-11 09:36:23

Pathological gambling, compulsive shopping, binge eating and other impulse control disorders appear to be more common among individuals taking dopamine agonist medications for Parkinson's disease, according to a report in the May issue of Archives of Neurology, one of the JAMA/Archives journals. These behaviors have been reported previously in patients with Parkinson's disease, according to background information in the article. Preliminary estimates of impulse control disorders in this...

2010-04-26 08:00:00

LAWRENCEVILLE, N.J., April 26 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets from Bristol-Myers Squibb Company (BMS). LODOSYN is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of Parkinson's disease, to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid...

2010-04-13 07:30:00

ATLANTA, April 13 /PRNewswire/ -- New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome (RLS) using rotigotine achieved sustained improvements in symptoms over 5 years of treatment. "Many people with RLS will have spent months or years trying to get a diagnosis and find a treatment that can help them. So these 5-year results provide additional evidence that, once they start using...

2010-04-08 07:30:00

ATLANTA, April 8 /PRNewswire/ -- Extensive new data on rotigotine will be presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada between April 10th and 17th, 2010. At a series of oral and poster presentations, leading international investigators will report the latest data on rotigotine in all stages of Parkinson's disease and in moderate to severe Restless Legs Syndrome (RLS). Oral presentations SP710 (5 year) Long-term Safety and Efficacy of Rotigotine...

2010-03-17 11:23:13

It has long been known that alcohol exposure is toxic to the developing fetus and can result in lifelong brain, cognitive and behavioral problems. Now, a new report out of UCLA shows that the effects of prenatal methamphetamine exposure "” or worse, a combination of methamphetamine and alcohol "” may be even more damaging. Reporting in the March 17 issue of the Journal of Neuroscience, UCLA professor of neurology Elizabeth Sowell and her colleagues used structural magnetic...

2010-01-12 07:00:00

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's extended-release formulation of pramipexole (pramipexole ER), which launched late last year in Europe and is expected to launch this year in the United States, will garner peak year sales of $250 to $500 million in the world's major pharmaceutical markets. The Pharmacor finding from the topic...

2010-01-11 19:55:43

In a world first, researchers identify and define dopamine agonist withdrawal syndrome, or DAWS New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by...

2009-12-21 13:30:00

Clinical study seeks to validate dyskinesia clinical scales, lowering hurdle to industry investment in new treatments NEW YORK, Dec. 21 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's...

2009-12-09 03:24:00

LONDON, Dec. 9 /PRNewswire/ -- The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief. With the introduction of newer dopamine agonists as well as fresh recommendations and treatment guidelines that call for using dopamine agonists as first-line therapy, the market is experiencing a...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related